Applied Genetic Technologies Corp. (NASDAQ:AGTC) had its price objective reduced by BMO Capital Markets from $25.00 to $20.00 in a research report released on Tuesday morning. They currently have an outperform rating on the stock.

Several other research analysts also recently commented on AGTC. Cantor Fitzgerald reissued a buy rating and set a $32.00 price objective on shares of Applied Genetic Technologies Corp. in a report on Wednesday, June 22nd. Wedbush decreased their target price on shares of Applied Genetic Technologies Corp. from $36.00 to $20.00 and set an outperform rating on the stock in a research report on Tuesday, September 13th. Stifel Nicolaus decreased their target price on shares of Applied Genetic Technologies Corp. from $29.00 to $24.00 and set a buy rating on the stock in a research report on Tuesday, September 13th. Janney Montgomery Scott cut shares of Applied Genetic Technologies Corp. from a buy rating to a sell rating and decreased their target price for the company from $23.00 to $11.00 in a research report on Tuesday, September 13th. Finally, Wells Fargo & Co. cut shares of Applied Genetic Technologies Corp. from an outperform rating to a market perform rating in a research report on Tuesday, September 13th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. Applied Genetic Technologies Corp. currently has an average rating of Hold and an average target price of $17.44.

Shares of Applied Genetic Technologies Corp. (NASDAQ:AGTC) opened at 8.92 on Tuesday. Applied Genetic Technologies Corp. has a 52-week low of $8.58 and a 52-week high of $21.43. The firm’s 50-day moving average price is $14.20 and its 200 day moving average price is $14.96. The company’s market capitalization is $161.03 million.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) last released its quarterly earnings data on Monday, September 12th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.07 by $0.08. Applied Genetic Technologies Corp. had a negative net margin of 2.92% and a negative return on equity of 1.34%. The business earned $12.10 million during the quarter. During the same period last year, the company earned ($0.48) EPS. The firm’s revenue for the quarter was up 1604.2% on a year-over-year basis. On average, equities analysts forecast that Applied Genetic Technologies Corp. will post ($0.61) earnings per share for the current year.

Hedge funds have recently bought and sold shares of the company. DUPONT CAPITAL MANAGEMENT Corp bought a new position in shares of Applied Genetic Technologies Corp. during the second quarter worth approximately $516,000. BlackRock Fund Advisors raised its position in shares of Applied Genetic Technologies Corp. by 3.7% in the first quarter. BlackRock Fund Advisors now owns 462,972 shares of the company’s stock worth $6,472,000 after buying an additional 16,541 shares during the period. Acrospire Investment Management LLC bought a new position in shares of Applied Genetic Technologies Corp. during the first quarter worth approximately $197,000. A.R.T. Advisors LLC raised its position in shares of Applied Genetic Technologies Corp. by 41.6% in the first quarter. A.R.T. Advisors LLC now owns 27,560 shares of the company’s stock worth $385,000 after buying an additional 8,100 shares during the period. Finally, BlackRock Institutional Trust Company N.A. raised its position in shares of Applied Genetic Technologies Corp. by 13.8% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 162,328 shares of the company’s stock worth $2,269,000 after buying an additional 19,736 shares during the period. 60.17% of the stock is currently owned by institutional investors.

About Applied Genetic Technologies Corp.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.

5 Day Chart for NASDAQ:AGTC

Receive News & Ratings for Applied Genetic Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.